NASDAQ:GMAB Genmab A/S (GMAB) Stock Price, News & Analysis → Top Project Outperforms BTC in 2023… (From Crypto 101 Media) (Ad) Free GMAB Stock Alerts $29.91 -0.72 (-2.35%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$29.84▼$30.5650-Day Range$26.43▼$31.6852-Week Range$26.32▼$42.99Volume361,389 shsAverage Volume547,105 shsMarket Capitalization$19.76 billionP/E Ratio31.16Dividend YieldN/APrice Target$48.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Genmab A/S alerts: Email Address Genmab A/S MarketRank™ Stock AnalysisAnalyst RatingHold2.38 Rating ScoreUpside/Downside62.2% Upside$48.50 Price TargetShort InterestHealthy0.31% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.22Based on 13 Articles This WeekInsider TradingN/AProj. Earnings Growth36.70%From $1.09 to $1.49 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.85 out of 5 starsMedical Sector256th out of 939 stocksPharmaceutical Preparations Industry116th out of 444 stocks 4.2 Analyst's Opinion Consensus RatingGenmab A/S has received a consensus rating of Hold. The company's average rating score is 2.38, and is based on 8 buy ratings, 2 hold ratings, and 3 sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $48.50, Genmab A/S has a forecasted upside of 62.2% from its current price of $29.91.Amount of Analyst CoverageGenmab A/S has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.31% of the float of Genmab A/S has been sold short.Short Interest Ratio / Days to CoverGenmab A/S has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Genmab A/S has recently increased by 10.22%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldGenmab A/S does not currently pay a dividend.Dividend GrowthGenmab A/S does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for GMAB. Previous Next 1.8 News and Social Media Coverage News SentimentGenmab A/S has a news sentiment score of 0.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 13 news articles for Genmab A/S this week, compared to 4 articles on an average week.Search InterestOnly 1 people have searched for GMAB on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Genmab A/S to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Genmab A/S insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.54% of the stock of Genmab A/S is held by insiders.Percentage Held by InstitutionsOnly 7.07% of the stock of Genmab A/S is held by institutions. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for Genmab A/S are expected to grow by 36.70% in the coming year, from $1.09 to $1.49 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Genmab A/S is 31.16, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 136.21.Price to Earnings Ratio vs. SectorThe P/E ratio of Genmab A/S is 31.16, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 182.24.Price to Earnings Growth RatioGenmab A/S has a PEG Ratio of 1.43. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioGenmab A/S has a P/B Ratio of 4.30. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Monument Traders AllianceMake This $3 Trade the Instant the Opening Bell RingsSince the birth of Wall Street, one simple rule has remained the same.... Buy stocks that are cheap....When they’re on sale…. And when nobody else is looking…See Why This $3.00 Stock Could Hit $15.00 About Genmab A/S Stock (NASDAQ:GMAB)Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.Read More GMAB Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GMAB Stock News HeadlinesMarch 28, 2024 | americanbankingnews.comGenmab A/S (NASDAQ:GMAB) Receives "Buy" Rating from HC WainwrightMarch 27, 2024 | americanbankingnews.comGenmab A/S (NASDAQ:GMAB) Receives Underweight Rating from Morgan StanleyMarch 29, 2024 | Crypto 101 Media (Ad)Top Project Outperforms BTC in 2023…According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.March 27, 2024 | americanbankingnews.comGenmab A/S (NASDAQ:GMAB) Receives Buy Rating from Truist FinancialMarch 25, 2024 | globenewswire.comTransactions in Connection with Share Buy-back ProgramMarch 23, 2024 | wsj.comGenmab A/S ADRMarch 20, 2024 | americanbankingnews.comGenmab A/S (NASDAQ:GMAB) Given Average Recommendation of "Hold" by BrokeragesMarch 18, 2024 | nz.finance.yahoo.comThe 10 best dressed from the 2024 NAACP Image AwardsMarch 29, 2024 | Crypto 101 Media (Ad)Top Project Outperforms BTC in 2023…According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.March 18, 2024 | globenewswire.comCompletion of share buy-back programMarch 15, 2024 | ca.finance.yahoo.comGMAB Apr 2024 30.000 putMarch 15, 2024 | msn.comBiogen chief medical officer departs, joins Alto Neuroscience boardMarch 15, 2024 | markets.businessinsider.comGenmab To Repurchase Up To DKK 3.5 Bln Of SharesMarch 15, 2024 | globenewswire.comGenmab Announces Initiation of Share Buy-Back ProgramMarch 13, 2024 | globenewswire.comTransactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated personsMarch 13, 2024 | globenewswire.comConstitution of the Board of Directors in Genmab A/S, Grant of Restricted Stock Units to Board Members and Employees and Grant of Warrants to Employees in GenmabMarch 13, 2024 | seekingalpha.comBeiGene gains as access to leukemia drug Brukinsa expandsMarch 11, 2024 | globenewswire.comTransactions in connection with share buy-back programMarch 4, 2024 | globenewswire.comTransactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated personsMarch 4, 2024 | globenewswire.comTransactions in connection with share buy-back programMarch 1, 2024 | globenewswire.comTransactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated personsMarch 1, 2024 | markets.businessinsider.comTruist Financial Reaffirms Their Buy Rating on Genmab (GMAB)February 29, 2024 | globenewswire.comTransactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated personsFebruary 27, 2024 | globenewswire.comTransactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated personsFebruary 27, 2024 | globenewswire.comCapital Increase in Genmab as a Result of Employee Warrant ExerciseFebruary 27, 2024 | markets.businessinsider.comGenmab's SBLA For Epcoritamab-bysp Granted Priority Review By FDAFebruary 27, 2024 | msn.comAbbVie/ Genmab win FDA priority review for lymphoma therapySee More Headlines Receive GMAB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Genmab A/S and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/14/2024Today3/29/2024Next Earnings (Estimated)5/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:GMAB CUSIPN/A CIK1434265 Webwww.genmab.com Phone(457) 020-2728FaxN/AEmployees2,204Year Founded1999Price Target and Rating Average Stock Price Target$48.50 High Stock Price Target$50.00 Low Stock Price Target$46.00 Potential Upside/Downside+62.2%Consensus RatingHold Rating Score (0-4)2.38 Research Coverage13 Analysts Profitability EPS (Most Recent Fiscal Year)$0.96 Trailing P/E Ratio31.16 Forward P/E Ratio27.44 P/E Growth1.43Net Income$631.91 million Net Margins26.50% Pretax Margin34.22% Return on Equity18.06% Return on Assets16.13% Debt Debt-to-Equity RatioN/A Current Ratio13.34 Quick Ratio13.32 Sales & Book Value Annual Sales$2.39 billion Price / Sales8.27 Cash Flow$1.21 per share Price / Cash Flow24.70 Book Value$6.95 per share Price / Book4.30Miscellaneous Outstanding Shares660,740,000Free Float650,570,000Market Cap$19.76 billion OptionableOptionable Beta0.98 Social Links The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesDr. Jan G.J. van de Winkel Ph.D. (Age 63)Co-Founder, President & CEO Comp: $2.9MMr. Anthony Pagano (Age 46)Executive VP & CFO Comp: $1.03MMs. Birgitte Stephensen M.Sc. (Age 63)Executive VP & Chief Legal Officer Comp: $638.88kDr. Martine J. van Vugt Ph.D. (Age 53)Executive VP & Chief Strategy Officer Comp: $696.97kMr. Martin Schultz (Age 48)Senior Director of Clinical Operations & Non-Independent Director Comp: $116.16kDr. Tahamtan Ahmadi (Age 51)Executive VP, Chief Medical Officer & Head of Experimental Medicines Comp: $1.12MDr. Mijke Zachariasse Ph.D. (Age 50)Senior Director, Head of Antibody Research Materials & Non-Independent Director Comp: $159.72kMr. Takahiro Hamatani (Age 49)Senior Director of Finance Japan & Non-Independent Director Comp: $116.16kMr. Anthony Mancini (Age 53)Executive VP & COO Comp: $1.1MMr. Andrew CarlsenSenior Director, VP & Head of Investor RelationsMore ExecutivesKey CompetitorsAlnylam PharmaceuticalsNASDAQ:ALNYBioMarin PharmaceuticalNASDAQ:BMRNTeva Pharmaceutical IndustriesNYSE:TEVABeiGeneNASDAQ:BGNEViatrisNASDAQ:VTRSView All CompetitorsInstitutional OwnershipPNC Financial Services Group Inc.Bought 8,463 shares on 3/22/2024Ownership: 0.025%Wellington Management Group LLPSold 56,050 shares on 3/5/2024Ownership: 0.359%Goldman Sachs Group Inc.Sold 108,410 shares on 3/1/2024Ownership: 0.080%Royal London Asset Management Ltd.Sold 26,451 shares on 3/1/2024Ownership: 0.034%Price T Rowe Associates Inc. MDSold 11,227 shares on 2/16/2024Ownership: 0.029%View All Institutional Transactions Should I Buy Genmab A/S Stock? GMAB Pros and Cons Explained Pros Here are some ways that investors could benefit from investing in Genmab A/S: Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases, showing a commitment to addressing critical medical needs. The company has a diverse product portfolio including DARZALEX, teprotumumab, and Amivantamab, targeting various types of cancer, which can potentially lead to revenue growth. Genmab A/S has collaborations with reputable companies like Seagen Inc., argenx, and AbbVie, enhancing its research and development capabilities and market reach. Recent developments indicate positive market sentiment towards Genmab A/S, with an average target price of $48.50, suggesting potential for stock price appreciation. The company is actively involved in pre-clinical programs, indicating a focus on innovation and future growth opportunities in the pharmaceutical industry. Cons Investors should be bearish about investing in Genmab A/S for these reasons: Genmab A/S operates in a highly competitive pharmaceutical industry, facing challenges such as regulatory hurdles, market competition, and potential patent expirations. The success of Genmab A/S heavily relies on the performance of its key products like DARZALEX and Amivantamab, making the company vulnerable to any setbacks in these products' development or commercialization. Investing in biopharmaceutical companies like Genmab A/S involves inherent risks related to clinical trial outcomes, regulatory approvals, and market acceptance of new treatments. Fluctuations in the healthcare sector, changes in healthcare policies, and unexpected events like pandemics can impact the financial performance and stock price of Genmab A/S. Investors should consider the potential impact of macroeconomic factors, currency fluctuations, and global market conditions on Genmab A/S's operations and financial results. These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Tuesday, March 26, 2024. Please send any questions or comments about these Genmab A/S pros and cons to contact@marketbeat.com. GMAB Stock Analysis - Frequently Asked Questions Should I buy or sell Genmab A/S stock right now? 13 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Genmab A/S in the last twelve months. There are currently 3 sell ratings, 2 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" GMAB shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GMAB, but not buy additional shares or sell existing shares. View GMAB analyst ratings or view top-rated stocks. What is Genmab A/S's stock price target for 2024? 13 brokerages have issued 1-year price targets for Genmab A/S's shares. Their GMAB share price targets range from $46.00 to $50.00. On average, they expect the company's stock price to reach $48.50 in the next twelve months. This suggests a possible upside of 62.2% from the stock's current price. View analysts price targets for GMAB or view top-rated stocks among Wall Street analysts. How have GMAB shares performed in 2024? Genmab A/S's stock was trading at $31.84 at the beginning of 2024. Since then, GMAB shares have decreased by 6.1% and is now trading at $29.91. View the best growth stocks for 2024 here. Are investors shorting Genmab A/S? Genmab A/S saw a increase in short interest in March. As of March 15th, there was short interest totaling 2,050,000 shares, an increase of 10.2% from the February 29th total of 1,860,000 shares. Based on an average trading volume of 623,600 shares, the days-to-cover ratio is currently 3.3 days. Approximately 0.3% of the company's stock are short sold. View Genmab A/S's Short Interest. When is Genmab A/S's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our GMAB earnings forecast. How were Genmab A/S's earnings last quarter? Genmab A/S (NASDAQ:GMAB) released its quarterly earnings results on Wednesday, February, 14th. The company reported $0.36 EPS for the quarter, topping analysts' consensus estimates of $0.34 by $0.02. The company earned $675.29 million during the quarter, compared to analysts' expectations of $678.14 million. Genmab A/S had a trailing twelve-month return on equity of 18.06% and a net margin of 26.50%. What ETFs hold Genmab A/S's stock? ETFs with the largest weight of Genmab A/S (NASDAQ:GMAB) stock in their portfolio include First Trust NYSE Arca Biotechnology Index Fund (FBT), iShares Biotechnology ETF (IBB), Goldman Sachs Future Health Care Equity ETF (GDOC), B.A.D. Etf (BAD), Range Cancer Therapeutics ETF (CNCR) and WisdomTree BioRevolution Fund (WDNA).ActivePassive International Equity ETF (APIE). What guidance has Genmab A/S issued on next quarter's earnings? Genmab A/S issued an update on its FY 2024 earnings guidance on Wednesday, February, 14th. The company provided EPS guidance of for the period. The company issued revenue guidance of $2.7 billion-$3.0 billion, compared to the consensus revenue estimate of $2.8 billion. What other stocks do shareholders of Genmab A/S own? Based on aggregate information from My MarketBeat watchlists, some companies that other Genmab A/S investors own include NVIDIA (NVDA), Alibaba Group (BABA), Johnson & Johnson (JNJ), CVS Health (CVS), Home Depot (HD), Intel (INTC), Pfizer (PFE), PayPal (PYPL), Verizon Communications (VZ) and Cisco Systems (CSCO). When did Genmab A/S IPO? Genmab A/S (GMAB) raised $503 million in an IPO on Thursday, July 18th 2019. The company issued 27,800,000 shares at $18.11 per share. BofA Merrill Lynch, Morgan Stanley and Jefferies served as the underwriters for the IPO and Guggenheim Securities and RBC Capital Markets were co-managers. Who are Genmab A/S's major shareholders? Genmab A/S's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Capital International Investors (0.61%), Harding Loevner LP (0.50%), Wellington Management Group LLP (0.36%), First Trust Advisors LP (0.19%), Envestnet Asset Management Inc. (0.14%) and Stifel Financial Corp (0.10%). How do I buy shares of Genmab A/S? Shares of GMAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:GMAB) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 Media“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyOnly a fool would buy Nvidia today… Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genmab A/S Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.